InflamaCORE
InflamaCORE is a privately held Miami-based LLC that states a focus on diagnosing and treating inflammatory diseases. The company has minimal public disclosure, with no products, pricing, customers, or funding detailed in available data.
- Company typePrivate
- Founded2022
- HeadquartersMiami, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
What InflamaCORE does
InflamaCORE, LLC is a privately held company headquartered in Miami, Florida, that states a focus on diagnosing and treating inflammatory diseases. The entity operates as a single-member-style LLC with no disclosed parent, subsidiary, or institutional investor relationships, and is led by Chief Executive Officer Stephen C. Glover. The company's public footprint is limited to a basic GoDaddy-hosted website (inflamacore.com) and a single contact email ([email protected]), with no product descriptions, pricing, customer segments, partnerships, or technology disclosures available in the input data.
The company was established in 2022 according to company history records and the website copyright notice, though firmographic data references 2009 — the 2022 date is treated as primary given direct corroboration from corporate records. No products, services, technology platforms, proprietary features, patents, certifications, or clinical pipeline are disclosed in the available source material, leaving the specific diagnostic or therapeutic offering undefined.
There is no disclosed revenue, funding history, headcount, pricing model, or go-to-market motion. The company has not announced institutional investment, M&A activity, partnerships, or product launches. Markets served are characterized as North America. Given the minimal disclosure, the company's current operational status appears to be early-stage or pre-commercial, with significant information gaps that limit financial and strategic assessment.
InflamaCORE firmographics
Firmographics- Name
- InflamaCORE
- Legal name
- InflamaCORE, LLC
- Website
- https://InflamaCORE.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- InflamaCORE is a privately held Miami-based LLC that states a focus on diagnosing and treating inflammatory diseases. The company has minimal public disclosure, with no products, pricing, customers, or funding detailed in available data.
- Ownership category
- akta.pro rank
InflamaCORE industry classification
Industry- Product category
- Specialty Healthcare / Inflammatory Disease Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (6215), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)
- akta.pro secondary industry
- Microbiome & Metagenomics Services (HLAGANAH)
Keywords
Where InflamaCORE is headquartered
LocationHeadquarters
- HQ city
- Miami
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
InflamaCORE business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D
InflamaCORE product offering
Product offeringCore offering
InflamaCORE is a specialty healthcare services company that focuses on diagnosing and treating inflammatory diseases. It operates as a private LLC providing clinical diagnostic and treatment services to patients suffering from inflammatory conditions, supported by an in-house technology capability referenced on its website.
Differentiator
Problem solved
Functional benefit
Products and services
- Inflammatory Disease Diagnostic & Treatment Services Clinical diagnostic and treatment services for patients with inflammatory diseases, as described by the company's stated specialization. Specific service lines, modalities, and protocols are not disclosed in the available source material.
Companies that use InflamaCORE
Customer profileIdeal customer profiles1 record
InflamaCORE technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
InflamaCORE partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights1 record
InflamaCORE competitors and assessment
Company assessmentBroad incumbents
- Eurofins Scientific: Global laboratory services group with clinical diagnostics capabilities including inflammation and autoimmune testing panels. Comparable as a multi-region diagnostics provider overlapping with InflamaCORE's inflammatory-disease testing and treatment-monitoring potential.
- AbbVie: Global biopharma leader in immunology and inflammation therapeutics (Humira, Rinvoq, Skyrizi). Comparable on the therapeutic side of InflamaCORE's stated mission; a major incumbent any inflammation-treating venture must compete against or partner with.
- Pfizer: Major biopharma with significant inflammation and immunology franchises (e.g., Cibinqo, Xeljanz, etrasimod). Comparable as a large, well-capitalized therapeutic competitor in the inflammatory disease treatment market InflamaCORE is targeting.
- Myriad Genetics: Diversified molecular diagnostics company with autoimmune and inflammation-relevant products (including acquired Crescendo Bioscience assets). Broader portfolio than InflamaCORE but overlapping in inflammation/autoimmune diagnostics and treatment-decision support.
- Quest Diagnostics: Largest US clinical laboratory offering broad inflammation and autoimmune test panels (e.g., CRP, ANA, cytokine assays). Comparable as a diagnostic-services backbone in inflammatory disease testing, though far broader in scope than a specialized inflammation player.
- Laboratory Corporation of America (Labcorp): Major clinical lab network with extensive autoimmune and inflammatory disease test menu. Comparable as a large-scale diagnostics provider overlapping with InflamaCORE's diagnostic ambitions, but operates across all major lab categories.
Emerging players
- Singulex: Developer of ultra-sensitive single-molecule immunoassay technology for inflammatory biomarker detection (e.g., IL-6, TNF-alpha). Comparable as a technology-focused inflammation biomarker company with partial overlap in measuring low-abundance inflammatory analytes.
- Meso Scale Diagnostics: Provides multiplexed assays for cytokines, chemokines, and other inflammatory biomarkers used in research and clinical studies. Comparable on the inflammation biomarker measurement axis, though primarily research-use rather than clinical-diagnostic focused.
Direct peers
- Crescendo Bioscience: Developed the Vectra DA test for rheumatoid arthritis disease activity, a blood-based multi-biomarker inflammation diagnostic. Directly comparable as a specialty inflammation diagnostics platform serving autoimmune patients and rheumatologists.
- Prometheus Laboratories: Specializes in diagnostic testing for inflammatory and autoimmune gastrointestinal diseases (e.g., IBD, Crohn's). Directly comparable to InflamaCORE's stated mission of diagnosing and treating inflammatory diseases, particularly in the gastroenterology-focused inflammation niche.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat1 record
Key risks6 records
Key highlights4 records
Customer concentration
InflamaCORE social profiles
Digital presenceInflamaCORE financial estimates
Financial estimateRevenue estimate
Valuation estimate
InflamaCORE leadership team
Management profileNumber of profiles
Profiles1 record
InflamaCORE funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InflamaCORE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InflamaCORE
What does InflamaCORE do?
InflamaCORE is a specialty healthcare services company that focuses on diagnosing and treating inflammatory diseases. It operates as a private LLC providing clinical diagnostic and treatment services to patients suffering from inflammatory conditions, supported by an in-house technology capability referenced on its website.
Is InflamaCORE a public or private company?
InflamaCORE is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was InflamaCORE founded?
InflamaCORE was founded in 2022. It employs 1 to 10 people.
Where is InflamaCORE based?
InflamaCORE is headquartered in Miami, United States, in the North America region.
Who are InflamaCORE's main competitors?
Broad incumbents on record are Eurofins Scientific, AbbVie, Pfizer, Myriad Genetics, Quest Diagnostics and Laboratory Corporation of America (Labcorp). Emerging players are Singulex and Meso Scale Diagnostics. Direct peers are Crescendo Bioscience and Prometheus Laboratories.
Does InflamaCORE have an API?
No public API is recorded for InflamaCORE.
What industry is InflamaCORE in?
InflamaCORE's product category is Specialty Healthcare / Inflammatory Disease Diagnostics. Its primary akta.pro industry code is HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms, with a secondary code of HLAGANAH, Microbiome & Metagenomics Services. Its NAICS code is 6215 and its SIC code is 8071.